A Patient with Platelets Deficient in Glycoprotein VI That Lack Both Collagen-induced Aggregation and Adhesion
Overview
Authors
Affiliations
Molecular level studies on platelets deficient in collagen-induced aggregation provide evidence for identifying possible platelet collagen receptors. We investigated platelets from a patient with mild bleeding time prolongation, but otherwise normal coagulation data. Her platelets lacked collagen-induced aggregation and adhesion, but retained normal aggregation and release by other agonists. Labeling her platelets with 125I or 3H and analysis by SDS-PAGE/autoradiography showed normal levels of glycoproteins Ia, Ib, IIa, IIb, IIIa, and IV. However, there were significantly decreased incorporations of both radioactivities into a 61-kD membrane glycoprotein (GP), which was identified as GPVI from its mobility on unreduced-reduced, two-dimensional SDS-PAGE. Sugiyama et al. (1987. Blood. 69: 1712) reported that the serum from an idiopathic thrombocytopenic purpura (ITP) patient contained an antibody against a 62-kD platelet protein. Our patient's platelets lacked the antigen for the ITP patient's antibody, demonstrating that the ITP serum contains a specific antibody against GPVI. The patient's parents' platelets contained approximately 50% the normal amount of GPVI, but still had normal collagen-induced aggregation and adhesion. The patient's platelets did not bind to types I and III collagen fibrils. Our results suggest that GPVI functions as a collagen receptor.
Tommasino A, Fiorentini V, Mattaroccia G, Scoccia A, Barbato E Rev Cardiovasc Med. 2024; 25(11):416.
PMID: 39618847 PMC: 11607508. DOI: 10.31083/j.rcm2511416.
Nakayama T, Saito R, Furuya S, Higuchi Y, Matsuoka K, Takahashi K Oncol Lett. 2024; 28(4):498.
PMID: 39211304 PMC: 11358723. DOI: 10.3892/ol.2024.14631.
Yamamoto A, Nishimori H, Shirai T, Takano K, Komura A, Kambara Y Intern Med. 2024; 63(13):1917-1922.
PMID: 38945933 PMC: 11272510. DOI: 10.2169/internalmedicine.2799-23.
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease.
Slater A, Khattak S, Thomas M Eur Heart J Cardiovasc Pharmacother. 2024; 10(5):465-473.
PMID: 38453424 PMC: 11323372. DOI: 10.1093/ehjcvp/pvae018.
Nakayama T, Saito R, Furuya S, Shoda K, Maruyma S, Takiguchi K Oncol Lett. 2023; 26(6):538.
PMID: 38020309 PMC: 10655057. DOI: 10.3892/ol.2023.14125.